Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: February 28, 2018

PharmAust receives $354k R&D Tax Incentive Refund

News & Announcements 2018By Richard Hopkins February 28, 2018

180127_R&D Refund

Recent Articles

January 9, PAA LUMC COVID-19 Research Update
January 8, 2021
December 31, Top 20 Shareholders
January 4, 2021
December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
December 23, 2020
December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

Punit @punitbansal14·

Dog cancer treatment - a significant market opportunity

🐕Cancer is the leading cause of death in the dogs
🐕Lymphoma & Hemangiosarcoma make up roughly one-third of canine cancers
🐕Approx. 6M cancer diagnosed in DOGS in the US each year

#monepantel🧬

Reply on Twitter 1353207150911356929 Retweet on Twitter 13532071509113569297 Like on Twitter 135320715091135692980 Twitter 1353207150911356929

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions